XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	KRW 1,016.00	+1.60%	45,875
10/09/26	KRW 1,000.00	0.00%	53,605
09/09/26	KRW 1,000.00	-1.67%	231,727
08/09/26	KRW 1,017.00	-7.96%	456,900
07/09/26	KRW 1,105.00	-0.09%	103,811

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 11/09/2026			5-day change	1st Jan Change
1,016.00 ^KRW	+1.60%		-8.14%	-38.83%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	17.57B 13.07M 11.28M 10.67M 9.7M 18.12M 1.25B 18.24M 127M 48.69M 630M 49.08M 48M 2.02B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	16.15B 12.02M 10.37M 9.8M 8.92M 16.65M 1.15B 16.77M 117M 44.76M 579M 45.11M 44.13M 1.85B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+1.60%
1 week	-8.14%
Current month	-14.77%
1 month	-26.59%
3 months	-29.93%
6 months	-27.43%
Current year	-38.83%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation : Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news : Xcell Therapeutics Inc.

News in other languages : Xcell Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	964	1,125
1 month	964	1,482
Current year	964	2,050
1 year	964	4,035
3 years	964	12,900
5 years	964	12,900
10 years	964	12,900

Manager	Title	Age	Since
U-Ri Lee CEO	Chief Executive Officer	54	01/09/2016
Soo-Rim Oh COO	Chief Operating Officer	65	-
Hae-Min Jeong CTO	Chief Tech/Sci/R&D Officer	40	-

Director	Title	Age	Since
U-Ri Lee BRD	Director/Board Member	54	01/09/2016
Hae-Min Jeong BRD	Director/Board Member	40	-
Mahn-Soon Hwang BRD	Director/Board Member	56	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+1.60%	-8.14%	-63.97%	-	13.11M
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.70%	+86.17%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+49.15%	+62.35%	640B
ABBVIE INC.	+0.83%	+0.26%	+17.76%	+72.25%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+30.13%	+35.17%	337B
NOVARTIS AG	-0.09%	-13.54%	+13.34%	+24.95%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-0.73%	+9.58%	246B
AMGEN INC.	-1.34%	-13.70%	+36.53%	+44.96%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.63%	-59.44%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+25.46%	+87.14%	178B
Average	-0.49%	-5.99%	+13.48%	+40.35%	350.48B
Weighted average by Cap.	-0.51%	-4.42%	+30.96%	+54.95%

	2024	2025
Net sales	1.93B 1.44M 1.24M 1.17M 1.07M 1.99M 137M 2.01M 13.95M 5.36M 69.31M 5.4M 5.28M 222M	1.95B 1.45M 1.25M 1.18M 1.08M 2.01M 139M 2.02M 14.06M 5.4M 69.84M 5.44M 5.32M 224M
Net income	-9.54B -7.1M -6.13M -5.79M -5.27M -9.84M -678M -9.91M -68.83M -26.44M -342M -26.65M -26.07M -1.1B	-10.93B -8.13M -7.02M -6.63M -6.03M -11.27M -777M -11.34M -78.82M -30.28M -392M -30.52M -29.85M -1.25B
Net Debt	-3.1B -2.31M -1.99M -1.88M -1.71M -3.2M -220M -3.22M -22.36M -8.59M -111M -8.66M -8.47M -356M	-1.42B -1.06M -911K -862K -784K -1.46M -101M -1.47M -10.24M -3.93M -50.86M -3.96M -3.88M -163M